CN105853741A - 一种降血糖的中药冲剂及其制备方法 - Google Patents
一种降血糖的中药冲剂及其制备方法 Download PDFInfo
- Publication number
- CN105853741A CN105853741A CN201610360438.XA CN201610360438A CN105853741A CN 105853741 A CN105853741 A CN 105853741A CN 201610360438 A CN201610360438 A CN 201610360438A CN 105853741 A CN105853741 A CN 105853741A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- blood sugar
- traditional chinese
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 239000008280 blood Substances 0.000 title claims abstract description 83
- 210000004369 blood Anatomy 0.000 title claims abstract description 82
- 235000000346 sugar Nutrition 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 20
- 244000207740 Lemna minor Species 0.000 claims abstract description 19
- 235000006439 Lemna minor Nutrition 0.000 claims abstract description 19
- 241001646834 Mesona Species 0.000 claims abstract description 19
- 240000000249 Morus alba Species 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 19
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 19
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 19
- 230000003247 decreasing effect Effects 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 29
- 239000012535 impurity Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000001816 cooling Methods 0.000 claims description 22
- 235000012907 honey Nutrition 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 235000000125 common agrimony Nutrition 0.000 claims description 19
- 241000233866 Fungi Species 0.000 claims description 18
- 241001165494 Rhodiola Species 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000010447 xylitol Nutrition 0.000 claims description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 14
- 229960002675 xylitol Drugs 0.000 claims description 14
- 239000000811 xylitol Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000003205 fragrance Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 38
- 208000024891 symptom Diseases 0.000 abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 206010036067 polydipsia Diseases 0.000 abstract description 2
- 235000016993 Agrimonia Nutrition 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 241000208368 Euonymus alatus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 241001506047 Tremella Species 0.000 abstract 1
- 235000007215 black sesame Nutrition 0.000 abstract 1
- 208000026500 emaciation Diseases 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 208000022530 polyphagia Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000034507 Haematemesis Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010049865 Achromotrichia acquired Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- -1 dihydro Catalpol glycosides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001415959 Grus japonensis Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- VDWSYBFEQXWINA-UHFFFAOYSA-N Martinoside Natural products C1=C(O)C(OC)=CC=C1CCOC1C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(OC(=O)C=CC=2C=C(O)C(OC)=CC=2)C(CO)O1 VDWSYBFEQXWINA-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WLWAYPFRKDSFCL-CNMJWYMJSA-N [(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC=C1CCO[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)[C@@H](CO)O1 WLWAYPFRKDSFCL-CNMJWYMJSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- RLGRBYHBNWLGER-UHFFFAOYSA-N cistanoside D Natural products C1=C(O)C(OC)=CC(CCOC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(OC(=O)C=CC=3C=C(OC)C(O)=CC=3)C(CO)O2)O)=C1 RLGRBYHBNWLGER-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NYCXYIWXBJWWIL-UHFFFAOYSA-N dihydrocatalpol Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2CCO1 NYCXYIWXBJWWIL-UHFFFAOYSA-N 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- ZMYQRHSOVRDQDL-NSWBACJASA-N leucosceptoside A Natural products COc1cc(C=CC(=O)O[C@@H]2[C@@H](CO)O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@H]2O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)ccc1O ZMYQRHSOVRDQDL-NSWBACJASA-N 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WLWAYPFRKDSFCL-AYPSUWEUSA-N martynoside Natural products COc1ccc(CCO[C@@H]2O[C@H](CO)[C@@H](OC(=O)C=Cc3ccc(O)c(OC)c3)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H]2O)cc1O WLWAYPFRKDSFCL-AYPSUWEUSA-N 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降血糖的中药冲剂及其制备方法,该中药冲剂取下述重量配比的中药原料制备而成:凉粉草20‑30份、桑椹10‑20份、黑芝麻10‑20份、盘龙参10‑20份、生地黄10‑20份、仙鹤草8‑16份、三七5‑15份、鬼箭羽5‑15份、银耳3‑13份、浮萍2‑8份、甘草2‑8份、红景天1‑5份。本发明降血糖的中药冲剂,采用常见中药材作为原料,配方科学,成本低廉,疗效显著,无副作用,具有降血糖、活血通络、益气滋阴、清热补肾的功效,可有效缓解高血糖引起的多饮、多尿、多食及消瘦的症状。
Description
技术领域
本发明涉及中医中药领域,特别是涉及一种降血糖的中药冲剂及其制备方法。
背景技术
高血糖为通常所说的“三高”中的一高。空腹血糖正常值在6.1mmol/L以下,餐后两小时血糖的正常值在7.8mmol/L以下,如果高于这一范围,称为高血糖。正常情况下,人体能够通过激素调节和神经调节这两大调节系统确保血糖的来源与去路保持平衡,使血糖维持在一定水平。但是在遗传因素(如糖尿病家族史)与环境因素(如不合理的膳食、肥胖等)的共同作用下,两大调节功能发生紊乱,就会出现血糖水平的升高。
血糖升高,尿糖增多,可引发渗透性利尿,从而引起多尿的症状;血糖升高、大量水分丢失,血渗透压也会相应升高,高血渗可刺激下丘脑的口渴中枢,从而引起口渴、多饮的症状;由于胰岛素相对或绝对的缺乏,导致体内葡萄糖不能被利用,蛋白质和脂肪消耗增多,从而引起乏力、体重减轻;为了补偿损失的糖分,维持机体活动,需要多进食;这就形成了典型的“三多一少”症状。
短时间、一次性的高血糖对人体无严重损害,随后血糖水平会逐渐恢复正常。然而长期的高血糖会使全身各个组织器官发生病变,导致急慢性并发症的发生。如失水、电解质紊乱、营养缺乏、抵抗力下降、肾功能受损、神经病变、眼底病变、心脑血管疾病、糖尿病足等。因此控制高血糖势在必行。
目前主要通过降糖药物治疗高血糖,降糖化学药可大致分为口服降糖药物和注射降糖药物。目前国内常用的口服降糖药物分为促胰岛素分泌剂类、二甲双胍类、α-糖苷酶抑制剂类、噻唑烷二酮衍生物等;其中促胰岛素分泌剂类又分为磺脲类和非磺脲类(格列奈类)。注射降糖药物有胰岛素及类似药物、GLP-1受体激动剂和DDP-4酶抑制剂等。长期使用降糖药物,患者有可能会出现强烈空腹感、出冷汗、全身无力、心悸、手脚发抖、眼睛发花、头疼、发呆等副作用。而降糖中药无上述副作用,且疗效更为理想。
发明内容
本发明的目的之一是克服现有技术的不足,提供一种制备简单、疗效显著、无副作用、服用方便的降血糖的中药冲剂。
为了解决上述技术问题,本发明所采用的技术方案是:
一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成:凉粉草20-30份、桑椹10-20份、黑芝麻10-20份、盘龙参10-20份、生地黄10-20份、仙鹤草8-16份、三七5-15份、鬼箭羽5-15份、银耳3-13份、浮萍2-8份、甘草2-8份、红景天1-5份。
一种降血糖的中药冲剂,优选的方案,取下述重量配比的中药原料制备而成:凉粉草22-28份、桑椹13-17份、黑芝麻13-17份、盘龙参13-17份、生地黄13-17份、仙鹤草10-14份、三七8-12份、鬼箭羽8-12份、银耳6-10份、浮萍4-6份、甘草4-6份、红景天2-4份。
一种降血糖的中药冲剂,更加优选的方案,取下述重量配比的中药原料制备而成:凉粉草25份、桑椹15份、黑芝麻15份、盘龙参15份、生地黄15份、仙鹤草12份、三七10份、鬼箭羽10份、银耳8份、浮萍5份、甘草5份、红景天3份。
本发明的另一目的是提供上述降血糖的中药冲剂的制备方法。
一种降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于40-50℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至80-120目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.2-0.3倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于40-50℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至80-120目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量8-12倍的水浸泡30-50分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取30-50min后,得到提取液,然后浓缩至85℃时相对密度为1.30-1.40的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀药物得到,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
上述降血糖的中药冲剂的制备方法,步骤一中将黑芝麻除杂,清洗晾干后,置于42-48℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至90-110目的细粉;优选的,将黑芝麻除杂,清洗晾干后,置于45℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至100目的细粉备用。
上述降血糖的中药冲剂的制备方法,步骤二中取原料重量0.23-0.27倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于42-48℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至90-110目的细粉备用;优选的,取原料重量0.25倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于45℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至100目的细粉备用。
上述降血糖的中药冲剂的制备方法,步骤三中加入原料重量9-11倍的水浸泡35-45分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取35-45min后,得到提取液,然后浓缩至85℃时相对密度为1.33-1.37的清膏;优选的,加入原料重量10倍的水浸泡40分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取40min后,得到提取液,然后浓缩至85℃时相对密度为1.35的清膏备用。
本发明所用主要中药原料的药理如下:
凉粉草:性寒,味甘、淡。归经无。功效与作用:消暑解渴、清热解毒。用治中暑口渴、湿火骨痛;近有用于糖尿病、高血压病。
桑椹:性寒,味甘、酸。归心经、肝经、肾经。功效与作用:补血滋阴、生津润燥。用治眩晕耳鸣、心悸失眠须发早白、津伤口渴、内热消渴、血虚便秘。
黑芝麻:性平,味甘。归肝经、肾经、大肠经。功效与作用:补肝肾、益精血、润肠燥。具有降低血糖、增加肝脏及肌肉中糖原的含量、增加肾上腺中抗坏血栓及胆固醇含量、抗衰老、通便、抑制肾上腺皮质功能等作用。用治头晕眼花、耳鸣耳聋、须发早白、病后脱发、肠燥便秘、肝肾不足、风痹、瘫痪、妇人乳少。
盘龙参 :性平,味甘、苦。归肺经、心经。功效与作用:益气养阴,清热解毒。主治病后虚弱,阴虚内热,咳嗽吐血,头晕,腰痛酸软,糖尿病,遗精,淋浊带下,咽喉肿痛,毒蛇咬伤,烫火伤,疮疡痈肿。
生地黄:性寒,味甘。归心经、肝经、肾经。含地黄苷、二氢梓醇苷、桃叶珊瑚苷、梓醇苷和多种氨基酸。药理实验证实,有降血糖、止血、抗弥漫性血管内凝血和抗炎免疫等作用。常用治热病舌绛烦渴、阴虚内热、骨蒸劳热、内热消渴、吐血衄血、发斑发疹。
仙鹤草:性平,味苦、涩。归心经、肝经。含仙鹤草素、仙鹤内脂、鞣质、甾醇、有机酸、酚性成分、皂苷、黄酮苷等。仙鹤草素有止血、调整心率、增加细胞抵抗力、降低血糖和消炎等作用。功效与作用:收敛止血、截疟、止痢、解毒。用治咯血、吐血、崩漏下血、疟疾、血痢、脱力劳伤、痈肿疮毒、阴痒带下。
三七:性温,味甘、微苦。归肝经、胃经。功效与作用:散瘀止血、消肿定痛,可增强免疫功能,保护肝功能,抗肿瘤,延缓衰老,降血糖,抗炎,调节物质代谢,促进生长。用治咯血、吐血、衄血、便血、崩漏、外伤出血、胸腹刺痛、跌扑肿痛。
鬼箭羽 :性寒,味苦。归肝经、脾经。功效与作用:行血通经、散瘀止痛,有降血糖作用。治月经不调、产后瘀血腹痛、跌打损伤肿痛、虫积腹痛。
银耳:性平,味甘。归肺经、胃经、肾经。功效与作用:润肺生津、滋阴养胃、益气和血、补髓强心、清肺热、济肾燥等功效。用治肺热咳嗽、肺燥干咳、久咳喉痒,咳痰带血、久咳络伤肋痛及肺痈、肺痿、月经不调、胃炎、大便秘结和下血等症。
浮萍:性寒,味辛。归肺经。功效与作用:宣散风热、透疹、利尿。治疗麻疹不透、风疹瘙痒、水肿尿少。
甘草:性平,味甘。归心经、胃经、脾经、肺经。含三萜皂苷、黄酮、香豆素等。功效与作用:补脾益气、止咳祛痰、缓急定痛、调和药性。此外,甘草有肾上腺皮质激素作用,抗炎、抗过敏反应,抗癌,抗菌,抗病毒,防止动脉硬化,抗脑缺血,预防糖尿病并发症等作用。治疗脾胃虚弱、中气不足、咳嗽气喘、痈疽疮毒、腹中挛急作痛、缓和药物烈性、解药毒。
红景天:性寒,味甘、涩。归肺经。功能主治:有补气清肺、益智养心、收涩止血、散瘀消肿的功效。抑制血糖升高作用,主治气虚体弱、病后畏寒、气短乏力、肺热咳嗽、咯血、白带腹泻、跌打损伤等。
与现有技术相比,本发明的有益效果为:
本发明降血糖的中药冲剂,采用常见中药材作为原料,配方科学,成本低廉,疗效显著,无副作用,具有降血糖、活血通络、益气滋阴、清热补肾的功效,可有效缓解高血糖引起的多饮、多尿、多食及消瘦的症状。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不被此限制。
实施例1一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成(每份取1g):凉粉草20份、桑椹10份、黑芝麻10份、盘龙参10份、生地黄10份、仙鹤草8份、三七5份、鬼箭羽5份、银耳3份、浮萍2份、甘草2份、红景天1份。
上述降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于40℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至80目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.2倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于40℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至80目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量8倍的水浸泡30分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取30min后,得到提取液,然后浓缩至85℃时相对密度为1.30的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
典型病例一:王xx,男,29岁,患者空腹血糖值7.4-8.0mmol/L,经常出现恶心,干呕,呕吐不断,腹部偶有胀痛,不消化,厌食,食欲大减,体重明显比原来轻等症状。医生给予其服用本发明实施例1中的降血糖的中药冲剂治疗,服用1周后,恶心、呕吐、厌食症状减轻,继续治疗半个月后,患者空腹血糖值稳定在5.8-6.0mmol/L,食欲增加,身体状况明显好转,无复发。
实施例2一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成(每份取1g):凉粉草30份、桑椹20份、黑芝麻20份、盘龙参20份、生地黄20份、仙鹤草16份、三七15份、鬼箭羽15份、银耳13份、浮萍8份、甘草8份、红景天5份。
上述降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于50℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至120目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.3倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于50℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至120目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量12倍的水浸泡50分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取50min后,得到提取液,然后浓缩至85℃时相对密度为1.40的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
实施例3一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成(每份取1g):凉粉草22份、桑椹13份、黑芝麻13份、盘龙参13份、生地黄13份、仙鹤草10份、三七8份、鬼箭羽8份、银耳6份、浮萍4份、甘草4份、红景天2份。
上述降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于42℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至90目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.23倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于42℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至90目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量9倍的水浸泡35分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取35min后,得到提取液,然后浓缩至85℃时相对密度为1.33的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
典型病例二:周xx,女,56岁,5年前患者血糖升高,出现多饮多食多尿,消瘦,易感染的症状,被诊断为糖尿病,长期采用降糖药控制血糖,但易反复,后医生给予其服用本发明实施例1中的降血糖的中药冲剂治疗,服用半月后,多饮多食多尿症状减轻,血糖有所下降,治疗1个月后,空腹血糖稳定在6.1mmol/L以下。
实施例4一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成(每份取1g):凉粉草28份、桑椹17份、黑芝麻17份、盘龙参17份、生地黄17份、仙鹤草14份、三七12份、鬼箭羽12份、银耳10份、浮萍6份、甘草6份、红景天4份。
上述降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于48℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至110目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.27倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于48℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至110目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量11倍的水浸泡45分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取45min后,得到提取液,然后浓缩至85℃时相对密度为1.37的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
实施例5一种降血糖的中药冲剂,取下述重量配比的中药原料制备而成(每份取1g):凉粉草25份、桑椹15份、黑芝麻15份、盘龙参15份、生地黄15份、仙鹤草12份、三七10份、鬼箭羽10份、银耳8份、浮萍5份、甘草5份、红景天3份。
上述降血糖的中药冲剂的制备方法,步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于45℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至100目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.25倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于45℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至100目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量10倍的水浸泡40分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取40min后,得到提取液,然后浓缩至85℃时相对密度为1.35的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
实验例:1、临床选择:为了验证本发明降血糖的中药冲剂的效果,我们抽取了400名患者进行了实验,平均分为两组,实验组及对照组。
2、入选标准:经确诊为高血糖的患者,空腹血糖值高于6.1mmol/L,餐后两小时血糖值高于7.8mmol/L,且非遗传性糖尿病。3、治疗方法:
治疗组:采用本发明实施例5中降血糖的中药冲剂,每次5g,每日2次。
对照组:服用迪沙片降糖药,每次 5mg,每日2次。
4、疗效情况判定标准:(1)有效:治疗1个月后,临床症状基本消失,空腹静脉血浆血糖3.9-6.0mmol/L,餐后静脉血浆血糖< 7.8mmol/L,无反弹。(2)无效:治疗1个月后,和治疗前相比较,各项理化检测指标无变化或症状加重。
精确对数据进行统计和数理分析,得到具体实验结果如下表:
经临床试验证明,采用本发明降血糖的中药冲剂与迪沙片降糖药相比,具有成本低廉、效果显著、无副作用、不易反弹的优点,经临床试验证明,本发明降血糖的中药冲剂的有效率为98%,可有效缓解高血糖引起的“三多一少”症状。
Claims (9)
1.一种降血糖的中药冲剂,其特征在于:取下述重量配比的中药原料制备而成:凉粉草20-30份、桑椹10-20份、黑芝麻10-20份、盘龙参10-20份、生地黄10-20份、仙鹤草8-16份、三七5-15份、鬼箭羽5-15份、银耳3-13份、浮萍2-8份、甘草2-8份、红景天1-5份。
2.根据权利要求1所述的一种降血糖的中药冲剂,其特征在于:取下述重量配比的中药原料制备而成:凉粉草25份、桑椹15份、黑芝麻15份、盘龙参15份、生地黄15份、仙鹤草12份、三七10份、鬼箭羽10份、银耳8份、浮萍5份、甘草5份、红景天3份。
3.一种根据权利要求1-2任一项所述的降血糖的中药冲剂的制备方法,其特征在于:步骤如下:
步骤一:将黑芝麻除杂,清洗晾干后,置于40-50℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至80-120目的细粉备用;
步骤二:将甘草除杂、洗净后,取原料重量0.2-0.3倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于40-50℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至80-120目的细粉备用;
步骤三:将凉粉草、桑椹、盘龙参、生地黄、仙鹤草、三七、鬼箭羽、银耳、浮萍、红景天分别除杂、洗净,粉碎至40目后,加入原料重量8-12倍的水浸泡30-50分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取30-50min后,得到提取液,然后浓缩至85℃时相对密度为1.30-1.40的清膏备用;
步骤四:将步骤一与步骤二得到的细粉、步骤三得到的清膏混合均匀得到药物,按药物:淀粉:木糖醇3:2:3的比例加入淀粉与木糖醇,搅拌混匀后干燥过40目筛,制成颗粒,包装成袋,即得降血糖的中药冲剂。
4.根据权利要求3所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤一中将黑芝麻除杂,清洗晾干后,置于42-48℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至90-110目的细粉备用。
5.根据权利要求4所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤一中将黑芝麻除杂,清洗晾干后,置于45℃的热锅内,用文火炒至有爆裂声及香气逸出时,取出,放凉后粉碎至100目的细粉备用。
6.根据权利要求3所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤二中取原料重量0.23-0.27倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于42-48℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至90-110目的细粉备用。
7.根据权利要求6所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤二中取原料重量0.25倍的炼蜜,用3倍开水溶化后,将甘草加入到溶化的炼蜜中,置于45℃锅内,文火加热,炒至深黄色不粘手时,取出放凉后粉碎至100目的细粉备用。
8.根据权利要求3所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤三中加入原料重量9-11倍的水浸泡35-45分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取35-45min后,得到提取液,然后浓缩至85℃时相对密度为1.33-1.37的清膏备用。
9.根据权利要求8所述的一种降血糖的中药冲剂的制备方法,其特征在于:步骤三中加入原料重量10倍的水浸泡40分钟,然后转移到超声容器中,在超声温度40℃,超声功率60W条件下提取40min后,得到提取液,然后浓缩至85℃时相对密度为1.35的清膏备用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610360438.XA CN105853741A (zh) | 2016-05-28 | 2016-05-28 | 一种降血糖的中药冲剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610360438.XA CN105853741A (zh) | 2016-05-28 | 2016-05-28 | 一种降血糖的中药冲剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105853741A true CN105853741A (zh) | 2016-08-17 |
Family
ID=56642171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610360438.XA Pending CN105853741A (zh) | 2016-05-28 | 2016-05-28 | 一种降血糖的中药冲剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105853741A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690783A (zh) * | 2013-12-25 | 2014-04-02 | 大连民族学院 | 用于治疗糖尿病的中药制剂及其制备方法 |
-
2016
- 2016-05-28 CN CN201610360438.XA patent/CN105853741A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690783A (zh) * | 2013-12-25 | 2014-04-02 | 大连民族学院 | 用于治疗糖尿病的中药制剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102871100B (zh) | 一种姜竹盐及其制备方法 | |
CN103463297B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法和用途 | |
CN104013845B (zh) | 一种降血糖中药制剂及制备方法 | |
CN104758844B (zh) | 一种治疗卵巢早衰的中药 | |
CN104873826A (zh) | 一种可清肺祛湿的茶饮及其制备方法 | |
CN104784245A (zh) | 一种治疗宫颈癌的药物 | |
CN104491531A (zh) | 一种治疗由糖尿病引起的消渴症的中药颗粒剂及其制备方法 | |
CN104524358B (zh) | 一种辅助治疗缺铁性贫血的药丸及制备方法 | |
CN105853741A (zh) | 一种降血糖的中药冲剂及其制备方法 | |
CN104547494A (zh) | 治疗甲亢的中药组合物药酒及制备工艺 | |
CN103623361A (zh) | 用于治疗脑血栓的中药组合物 | |
CN108186799A (zh) | 地骨五加散及制备方法 | |
CN104689138A (zh) | 一种治疗胃溃疡的养胃健食片及其制备方法 | |
CN102716341B (zh) | 治疗急性消化性溃疡出血的中药组合物及其制备方法 | |
CN107260890A (zh) | 一种复方速效补血生血剂及应用 | |
CN105288166A (zh) | 一种用于甲状腺肿大的中药组合物及其制备方法 | |
CN106266427A (zh) | 一种治疗肾病的中药药酒及其制备方法 | |
CN105878796A (zh) | 一种治疗ⅱ型糖尿病合并血脂异常的醋饮及其制备方法 | |
CN105456951A (zh) | 一种治疗乳房纤维腺瘤的中药制剂及其制备方法 | |
CN104784587A (zh) | 一种治疗内分泌失调型不孕的中药组合物及其制备方法 | |
CN105056160A (zh) | 一种治疗奶牛缺乳症的药物组合物及其制备方法 | |
CN104940710A (zh) | 天竺黄痫康宁中药组合物及其制备方法 | |
CN105169035A (zh) | 一种治疗小儿急性腹泻的灌肠剂及制法 | |
CN105031389A (zh) | 一种配合放疗法抑制恶性肿瘤繁殖的中药片剂及制法 | |
CN106031463A (zh) | 一种西红花活血化瘀酸汤料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160817 |
|
WD01 | Invention patent application deemed withdrawn after publication |